Biotech entity
pharma is the sole category represented across all 1 tracked stories. Biosidus is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Mubadala Bio, all published on July 27, 2026.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Biosidus is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Mubadala Bio, all published on July 27, 2026. Each carries 1 original source on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mubadala Bio. Shared-story counts are live from our verified record — not editorial picks.
Biosidus, a Latin American biotech, signed a licensing deal with Mubadala Bio at BIO 2026 to introduce four biologic therapies—including epoetin alfa and filgrastim—into the UAE via DiabTec. The move advances local pharma manufacturing and expands Biosidus' global footprint.
Source: prnewswire.com
Mubadala Bio is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
